Omnicell - OMCL Stock Forecast, Price & News

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

Wall Street Analyst Weigh In

Several research firms have commented on OMCL. SVB Leerink began coverage on shares of Omnicell in a report on Friday, July 15th. They issued a "market perform" rating and a $124.00 price objective on the stock. Piper Sandler cut their price objective on shares of Omnicell from $162.00 to $150.00 and set an "overweight" rating for the company in a research report on Monday, August 8th. TheStreet lowered Omnicell from a "b-" rating to a "c+" rating in a research note on Tuesday, May 17th. BTIG Research reduced their price target on Omnicell from $190.00 to $175.00 and set a "buy" rating for the company in a research note on Wednesday, July 27th. Finally, Wells Fargo & Company lowered their price objective on Omnicell from $188.00 to $158.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 3rd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Omnicell currently has an average rating of "Moderate Buy" and an average target price of $162.40.

Omnicell Price Performance

NASDAQ:OMCL traded down $0.88 during trading hours on Tuesday, reaching $111.35. 277,822 shares of the company were exchanged, compared to its average volume of 499,687. The company has a market capitalization of $4.93 billion, a P/E ratio of 88.37, a P/E/G ratio of 3.64 and a beta of 1.05. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.11 and a quick ratio of 1.71. The business has a 50 day moving average of $112.51 and a 200 day moving average of $121.08. Omnicell has a 1-year low of $103.62 and a 1-year high of $187.29.

Omnicell (NASDAQ:OMCL - Get Rating) last released its earnings results on Thursday, August 4th. The company reported $0.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.85 by ($0.01). The company had revenue of $331.39 million for the quarter, compared to analyst estimates of $339.45 million. Omnicell had a return on equity of 10.37% and a net margin of 4.82%. The business's revenue for the quarter was up 21.5% compared to the same quarter last year. During the same period last year, the company posted $0.71 earnings per share. Research analysts forecast that Omnicell will post 2.75 EPS for the current year.

Insider Activity at Omnicell

In other news, EVP Scott Peter Seidelmann sold 3,765 shares of Omnicell stock in a transaction on Thursday, June 16th. The stock was sold at an average price of $110.15, for a total value of $414,714.75. Following the transaction, the executive vice president now owns 40,789 shares in the company, valued at approximately $4,492,908.35. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 2.76% of the stock is currently owned by insiders.